Structure of compound 4d

oral selective PI3K_ kinase inhibitor

<10 mg proj. human dose

from virtual screening and opt.

ACS Med. Chem. Lett., Nov. 19, 2020

Merck, Boston, CA

“compound 4d” (Merck oral selective PI3K delta kinase inhibitor)

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.